{"id":"NCT02339090","sponsor":"Versartis Inc.","briefTitle":"Long-Acting Growth Hormone in Children Compared to Daily rhGH","officialTitle":"Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children With Growth Hormone Deficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-26","primaryCompletion":"2017-08-23","completion":"2017-08-23","firstPosted":"2015-01-15","resultsPosted":"2022-12-30","lastUpdate":"2022-12-30"},"enrollment":138,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Growth Disorders"],"interventions":[{"type":"DRUG","name":"Somavaratan","otherNames":["Long-acting recombinant human growth hormone","VRS-317"]},{"type":"DRUG","name":"rhGH","otherNames":["daily growth hormone","recombinant growth hormone therapy"]}],"arms":[{"label":"Somavaratan","type":"EXPERIMENTAL"},{"label":"rhGH","type":"ACTIVE_COMPARATOR"}],"summary":"The trial will compare a twice-monthly somavaratan dosing regimen for non-inferiority of treatment effect against daily injections of rhGH.","primaryOutcome":{"measure":"Annual Height Velocity","timeFrame":"12 months","effectByArm":[{"arm":"Somavaratan","deltaMin":9.43,"sd":0.28},{"arm":"rhGH","deltaMin":10.7,"sd":0.48}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":104},"commonTop":["Pyrexia","Injection site pain","Headache","Cough","Vomiting"]}}